| Species |
Human |
| Protein Construction |
SLAMF7 (Ser23-Met226)
Accession # Q9NQ25 |
Poly-His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
≤ 1 EU/μg of protein by LAL method |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CS1/CRACC/SLAMF7, His & Avi, Human at 1μg/ml (100μl/well) on the plate can bind AntiSLAMF7 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
25.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 μg/ml. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized SLAMF7, His & Avi tag at 1 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA.
Recombinant Human CRACC/SLAMF7 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.
The purity of Recombinant Human CRACC/SLAMF7 Protein is greater than 95% as determined by SEC-HPLC.
Immobilized CS1/CRACC/SLAMF7, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 2.2 ng/ml determined by ELISA.
The purity of CS1/CRACC/SLAMF7, His & Avi, Human is greater than 95% as determined by SEC-HPLC.
CS1/CRACC/SLAMF7, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family, a self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune responses. |
| Synonyms |
CD319 antigen; CD319; 19A; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CRACC; CRACCCD2-like receptor-activating cytotoxic cells; CS119A24 protein; Membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; Novel Ly9; Protein 19A; SLAM family member 7; SLAMF7; CS1 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
